TP53 and gastric cancer: It is worth noting that the presence of amplifications of tyrosine kinase receptor genes or cell cycle mediators, characteristic of stable TP53-mutated GC, along with other frequently observed alterations among GC subtypes such as PIK3CA mutation, holds potential therapeutic value.